Christine E Cherella1, Henry A Feldman2, Monica Hollowell3, Danielle M Richman4, Edmund S Cibas5, Jessica R Smith1, Trevor E Angell6, Zhihong Wang6, Erik K Alexander6, Ari J Wassner1. 1. Division of Endocrinology, Boston Children's Hospital, Boston, Massachusetts. 2. Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, Massachusetts. 3. Department of Pathology, Boston Children's Hospital, Boston, Massachusetts. 4. 4Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts. 5. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. 6. Division of Endocrinology, Hypertension, and Diabetes, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
Context: Most pediatric thyroid nodules are cytologically benign, but few data exist to guide treatment. Objective: To describe the natural history and outcomes of cytologically benign, pediatric thyroid nodules. Design: Cohort study. Setting: Multidisciplinary thyroid clinic at an academic medical center. Patients: Consecutive pediatric patients (≤18 years old) with cytologically benign thyroid nodules evaluated between 1998 and 2016. Results: Cytologically benign nodules (N = 237) in 181 patients were followed by ultrasound (median follow-up, 3.4 years; range, 0.5 to 13.9 years) or to resection. Thyroid cancer was diagnosed in six nodules (2.5%), and all six patients were disease free after median follow-up of 4.9 years. Malignancy was more common in nodules >4 cm (15.4%; P = 0.037) or that grew during follow-up (6.0%; P = 0.048). The likelihood of nodule growth (±SE) was 15% ± 3%, 24% ± 4%, and 49% ± 10% at 6, 12, and 24 months, respectively. Among nodules >2 cm, those with ≥25% cystic content grew more slowly than nodules <25% cystic; nodules <2 cm grew similarly regardless of cystic content. Conclusion: Benign cytology in pediatric thyroid nodules has a low false-negative rate similar to that in adults, and prognosis is excellent in the rare cases of malignancy. Resection of nodules >4 cm, combined with surveillance of smaller nodules and repeated aspiration for growth, detects most false-negative results. Follow-up ultrasound in 12 months is appropriate for most cytologically benign pediatric nodules, but delaying surveillance up to 24 months may be reasonable in large, predominantly cystic nodules.
Context: Most pediatric thyroid nodules are cytologically benign, but few data exist to guide treatment. Objective: To describe the natural history and outcomes of cytologically benign, pediatric thyroid nodules. Design: Cohort study. Setting: Multidisciplinary thyroid clinic at an academic medical center. Patients: Consecutive pediatric patients (≤18 years old) with cytologically benign thyroid nodules evaluated between 1998 and 2016. Results: Cytologically benign nodules (N = 237) in 181 patients were followed by ultrasound (median follow-up, 3.4 years; range, 0.5 to 13.9 years) or to resection. Thyroid cancer was diagnosed in six nodules (2.5%), and all six patients were disease free after median follow-up of 4.9 years. Malignancy was more common in nodules >4 cm (15.4%; P = 0.037) or that grew during follow-up (6.0%; P = 0.048). The likelihood of nodule growth (±SE) was 15% ± 3%, 24% ± 4%, and 49% ± 10% at 6, 12, and 24 months, respectively. Among nodules >2 cm, those with ≥25% cystic content grew more slowly than nodules <25% cystic; nodules <2 cm grew similarly regardless of cystic content. Conclusion: Benign cytology in pediatric thyroid nodules has a low false-negative rate similar to that in adults, and prognosis is excellent in the rare cases of malignancy. Resection of nodules >4 cm, combined with surveillance of smaller nodules and repeated aspiration for growth, detects most false-negative results. Follow-up ultrasound in 12 months is appropriate for most cytologically benign pediatric nodules, but delaying surveillance up to 24 months may be reasonable in large, predominantly cystic nodules.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Elmira Amirazodi; Evan J Propst; Catherine T Chung; Dimitri A Parra; Jonathan D Wasserman Journal: Cancer Cytopathol Date: 2016-07-14 Impact factor: 5.284
Authors: Sara E Monaco; Liron Pantanowitz; Walid E Khalbuss; Vanessa A Benkovich; John Ozolek; Marina N Nikiforova; Jeffrey P Simons; Yuri E Nikiforov Journal: Cancer Cytopathol Date: 2012-05-17 Impact factor: 5.284
Authors: Erik K Alexander; Shelley Hurwitz; Jenny P Heering; Carol B Benson; Mary C Frates; Peter M Doubilet; Edmund S Cibas; P Reed Larsen; Ellen Marqusee Journal: Ann Intern Med Date: 2003-02-18 Impact factor: 25.391
Authors: Alex C Essenmacher; Peter H Joyce; Simon C Kao; Monica Epelman; Liuska M Pesce; Michael P D'Alessandro; Yutaka Sato; Craig M Johnson; Daniel J Podberesky Journal: Radiographics Date: 2017-10 Impact factor: 5.333
Authors: Eric Nou; Norra Kwong; Lukas K Alexander; Edmund S Cibas; Ellen Marqusee; Erik K Alexander Journal: J Clin Endocrinol Metab Date: 2013-11-25 Impact factor: 5.958
Authors: Christine E Cherella; Trevor E Angell; Danielle M Richman; Mary C Frates; Carol B Benson; Francis D Moore; Justine A Barletta; Monica Hollowell; Jessica R Smith; Erik K Alexander; Edmund S Cibas; Ari J Wassner Journal: Thyroid Date: 2019-08 Impact factor: 6.568